Roche

News

MHRA imposes restrictions on acne drug in children

The UK medicines regulator has tightened up controls on the prescription of acne treatment isotretinoin to patients under the age of 18, following a review prompted by con

News

Despite trial miss, Sarepta plans new filing for DMD therapy

Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy has failed to meet its primary objective in a phase 3 trial, but the company says it will file to extend

News

FDA clears Roche’s Vabysmo for retinal vein occlusion

Roche has claimed a third approval from the FDA for its eye disease therapy Vabysmo – already its fastest-growing product – that could make it an option for hundreds of th

News

Rumour confirmed as Roche buys Telavant for $7.1bn

Roche has announced a $7.1 billion deal to acquire Roivant group company Telavant and its RVT-301 drug candidate for inflammatory bowel disease (IBD), confirming rumours t

News

ESMO: Roche’s Alecensa claims a first in ALK-positive NSCLC

Roche’s Alecensa has become the first drug in the ALK inhibitor class to significantly improve disease-free survival across all disease stages in a phase 3 trial involving

News

Roche sticks with molecular glue, partnering Monte Rosa

Roche seems determined to develop a commanding position in the emerging molecular glue category, signing up to a $2 billion partnership with Monte Rosa Therapeutics that i

MHRA imposes restrictions on acne drug in children

Despite trial miss, Sarepta plans new filing for DMD therapy

FDA clears Roche’s Vabysmo for retinal vein occlusion

Rumour confirmed as Roche buys Telavant for $7.1bn

ESMO: Roche’s Alecensa claims a first in ALK-positive NSCLC

Roche sticks with molecular glue, partnering Monte Rosa

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

Roche

Editor's Picks